To the full analysis
Buyback calculator for 10x Genomics
10x Genomics stock: key metrics
TXG10x Genomics had an operating margin of −17.2% and a return on invested capital (ROIC) of −21.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | 85.1% | −25.8% | −26.4% |
| 2018 | 80.4% | −75.7% | −76.9% |
| 2019 | 75.2% | −11.8% | −12.7% |
| 2020 | 80.4% | −28.6% | −181.6% |
| 2021 | 84.9% | −10.8% | −11.9% |
| 2022 | 76.7% | −32.5% | −32.1% |
| 2023 | 66.2% | −42.9% | −41.2% |
| 2024 | 67.9% | −31.9% | −29.9% |
| 2025 | 69.1% | −17.2% | −6.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | 16.7% | −25.2% | −24.8% |
| 2018 | 51.1% | no data | −90.5% |
| 2019 | −7.4% | −7.1% | −5.2% |
| 2020 | −73.4% | −9.9% | −58.4% |
| 2021 | −7.1% | −18.6% | −5.7% |
| 2022 | −20.6% | −33.9% | −16.1% |
| 2023 | −34.4% | −45.6% | −26.4% |
| 2024 | −25.7% | −36.3% | −19.9% |
| 2025 | −5.5% | −21.1% | −4.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 May 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.